CANNABINOID RECEPTOR EXPRESSION AND THE EFFECT OF OLORINAB, A PERIPHERALLY ACTING, HIGHLY SELECTIVE, FULL AGONIST OF THE CANNABINOID RECEPTOR 2 (CB2), IN RODENTS WITH COLITIS AND CHRONIC VISCERAL HYPERSENSITIVITY

被引：0
|
作者：
Castro, Joel
Maddern, Jessica
Garcia-Caraballo, Sonia
Schober, Gudrun
Lindstrom, Beatriz
Schmiel, Shirdi
Brierley, Stuart
机构：
来源：
GASTROENTEROLOGY | 2020年 / 158卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1078
引用
收藏
页码：S269 / S269
页数：1
相关论文
共 50 条
  • [1] Olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), reduces visceral hypersensitivity in mice
    Castro, Joel
    Maddern, Jessica
    Garcia-Caraballo, Sonia
    Schober, Gudrun
    Lindstrom, Beatriz
    Schmiel, Shirdi
    Brierley, Stuart M.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2020, 32
  • [2] Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents
    Castro, Joel
    Garcia-Caraballo, Sonia
    Maddern, Jessica
    Schober, Gudrun
    Lumsden, Amanda
    Harrington, Andrea
    Schmiel, Shirdi
    Lindstrom, Beatriz
    Adams, John
    Brierley, Stuart M.
    PAIN, 2022, 163 (01) : E72 - E86
  • [3] OLORINAB (FORMERLY APD371), A PERIPHERALLY RESTRICTED, HIGHLY SELECTIVE, FULL AGONIST OF THE CANNABINOID RECEPTOR 2 (CB2), REDUCES VISCERAL HYPERSENSITIVITY IN ANIMAL MODELS
    Castro, Joel
    Maddern, Jessica
    Garcia-Caraballo, Sonia
    Lumsden, Amanda L.
    Lindstrom, Beatriz
    Adams, John
    Brierley, Stuart
    GASTROENTEROLOGY, 2019, 156 (06) : S382 - S382
  • [4] Olorinab (APD371), a peripherally restricted, highly selective, full agonist of the cannabinoid receptor type 2 (CB2), reduces visceral hypersensitivity in animal models
    Castro, J.
    Maddern, J.
    Garcia-Caraballo, S.
    Lumsden, A.
    Lindstrom, B.
    Adams, J.
    Brierley, S. M.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2019, 31
  • [5] APD371, a peripherally restricted, highly selective, full agonist of the Cannabinoid Receptor 2 (CB2), reduces colitis-induced visceral hypersensitivity in rats
    Brierley, S.
    Castro, J.
    Maddern, J.
    Garcia-Caraballo, S.
    Lindstrom, B.
    Adams, J.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2018, 30
  • [6] PHARMACOKINETICS (PK) AND SAFETY OF OLORINAB (APD371), A HIGHLY SELECTIVE, PERIPHERALLY ACTING FULL AGONIST OF THE CANNABINOID RECEPTOR 2 (CB2), IN HEALTHY ADULT SUBJECTS.
    Stauber, K.
    Oh, D.
    Tang, Y.
    Lindstrom, B.
    English, B.
    Cabell, C.
    Ruckle, J.
    Searle, S.
    Kam, J.
    Jones, R.
    Grundy, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S79 - S79
  • [7] Cannabichromene is a cannabinoid CB2 receptor agonist
    Udoh, Michael
    Santiago, Marina
    Devenish, Steven
    McGregor, Iain S.
    Connor, Mark
    BRITISH JOURNAL OF PHARMACOLOGY, 2019, 176 (23) : 4537 - 4547
  • [8] Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates
    Gonsiorek, W.
    Lunn, C. A.
    Fan, X.
    Deno, G.
    Kozlowski, J.
    Hipkin, R. W.
    BRITISH JOURNAL OF PHARMACOLOGY, 2007, 151 (08) : 1262 - 1271
  • [9] Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis
    El Bakali, Jamal
    Muccioli, Giulio G.
    Body-Malapel, Mathilde
    Djouina, Madjid
    Klupsch, Frederique
    Ghinet, Alina
    Barczyk, Amelie
    Renault, Nicolas
    Chavatte, Philippe
    Desreumaux, Pierre
    Lambert, Didier M.
    Millet, Regis
    ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (02): : 198 - 203
  • [10] Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease
    Yacyshyn, Bruce R.
    Hanauer, Stephen
    Klassen, Preston
    English, Brett A.
    Stauber, Kathe
    Barish, Charles F.
    Gilder, Kye
    Turner, Stewart
    Higgins, Peter D. R.
    CROHNS & COLITIS 360, 2021, 3 (01)
12345